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ABSTRACT
Introduction: Retail pharmacies provide 
regular prescription drugs and some specialty 
prescription drugs,  whereas specialty 
pharmacies focus on distributing specialty 
prescription drugs, including tumor necrosis 
factor (TNF) antagonists. It is unknown whether 
pharmacy type impacts patients’ adherence to 
anti-TNF therapy. The relationship between 
pharmacy type (specialty vs. retail) and refill 
adherence to therapy with the TNF antagonist 
adalimumab was examined. Methods: This was 
a retrospective analysis of dispensing records 
of patients in the United States who were 
prescribed a TNF antagonist (adalimumab 40 mg 
per 0.8-mL injection) during a dispensation 
period from January 2003 to August 2009. 
Patients treated with adalimumab were 




For each patient, medication refill adherence 
(MRA) was calculated as total days of supply 
divided by total number of days evaluated, 
multiplied by 100. A regression analysis was 
conducted in which the dependent variable was 
MRA and the independent variables included 
pharmacy type (specialty vs. retail pharmacy), 
reimbursement/payment type, copayment/
payment amount per prescription, age, sex, 
ethnicity, and annual income. Results: Of the 
86,079 patients included, 70% obtained the 
medication from a specialty pharmacy, 92% 
were members of Blue Cross and Blue Shield 
plans, 67% were women, and 81% were white. 
The average MRA was 84, and the average age 
was 52 years. Significant predictors (P<0.05) of 
MRA included pharmacy type, reimbursement/
payment type, copayment/payment amount 
per prescription, age, sex, and ethnicity; and 
pharmacy type was the strongest predictor. 
When other independent variables were 
controlled for, MRA was 16% less for patients 
who used a retail pharmacy vs. patients who 
used a specialty pharmacy. Conclusion: Patients 
who used a specialty pharmacy to fulfill 
prescriptions for a TNF antagonist had a greater 
refill adherence than did patients who used a 
retail pharmacy.
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INTRODUCTION
In the United States, there are different 
approaches to classify a pharmacy in the 
ambulatory care setting. For example, for 
pharmacy ownership, a pharmacy can be 
categorized primarily as a chain pharmacy, 
an independent pharmacy, or an outpatient 
pharmacy of a health institution.1 In addition, 
from the perspective of drug inventory or 
distribution, a pharmacy can be classified 
mainly as a retail pharmacy (a traditional 
pharmacy), which provides general prescription 
drugs and some specialty prescription drugs, or 
a specialty pharmacy, which specializes in the 
distribution of specialty prescription drugs.2 
These specialty medications include high-cost 
injectable, infused, oral, and inhaled therapies 
for conditions that require complex care, such as 
rheumatoid arthritis, multiple sclerosis, cancer, 
and hemophilia.3
In 2004, less than 3% of private health 
plan members used specialty medications.3 
However, because of their high costs, specialty 
medications represented an estimated 
$35 billion market in 2006, which accounted 
for 16% of expenditures on prescription drugs 
in 2006.4,5 According to Aon Consulting’s 
Spring 2009 Health Care Trend Survey, the rate 
of increase in specialty drug costs was forecasted 
to be 13.2% per year, which was approximately 
4% greater than the rate for general drug costs.6 
Recently, pharmacy benefit management 
companies and specialty pharmacies have 
been consolidating.7,8 For instance, pharmacy 
benefit management companies have acquired 
or allied with existing specialty pharmacies or 
created their own specialty pharmacies from 
mail-order facilities.
Tumor necrosis factor (TNF) antagonists are a 
therapeutic class of specialty prescription drugs 
for the treatment of autoimmune disorders, 
such as rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis, and Crohn’s disease.9 In 
the ambulatory care setting in the United States, 
the most frequently prescribed TNF antagonists 
are etanercept, infliximab, adalimumab, and 
certolizumab pegol. Patients prescribed these 
medications can obtain them through a retail 
pharmacy or a specialty pharmacy. Previous 
research showed that nonadherence to anti-TNF 
therapy is associated with poor outcomes.10 Thus, 
it is important to identify predictors of adherence 
that can potentially be modified to better design 
strategies for improving patients’ adherence.
Medication adherence is defined as “the 
extent to which a patient acts in accordance 
with the prescribed interval and dose of a dosing 
regimen.”11 Inadequate adherence may result 
in negative health outcomes, such as increased 
morbidity and mortality.12,13 Adherence may be 
affected by myriad factors related to the cost, 
the dosage form, the medical condition, the 
patient, the healthcare provider, the relationship 
between the patient and the healthcare provider, 
or the environment in which the medication 
is used.13-15 A systems approach to predicting 
patients’ adherence behaviors considers how 
the environment, including healthcare delivery 
systems, affects patients’ adherence.16 The 
pharmacy or pharmaceutical care service are 
components of the healthcare system that can 
have an impact on patients’ adherence.17-19
The research in system-related factors is 
limited and not conclusive. Two studies explored 
the relationship between pharmacy type and 
medication adherence to therapy with specialty 
medications. One study compared patients with 
hepatitis C who used a specialty pharmacy vs. 
a retail pharmacy, and found no difference 
in therapy completion rates.20 Another study 
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revealed that patients with multiple sclerosis or 
inflammatory conditions who used a specific 
specialty pharmacy had lower rates of therapy 
discontinuation than those using a retail 
pharmacy or another specialty pharmacy.21 
Specialty pharmacies may be better equipped 
to provide specialty medications compared 
with retail pharmacies. For example, retail 
pharmacies may have limited capacity for 
storage and delivery, lack of direct access to 
payers, unavailability of pharmacists beyond 
regular store hours, and limited supplies of 
accessories (eg, needle, syringe, alcohol swab, 
etc).2 In this study, the relationship between 
two types of pharmacies (specialty vs. retail) and 
patients’ refill adherence to therapy with a TNF 
antagonist was examined. It was hypothesized 
that patients who obtained the TNF antagonist 
from a specialty pharmacy would have a greater 
medication refill adherence (MRA) than those 
who obtained the drug from a retail pharmacy.
METHODS
Design and Original Data
This study was a retrospective analysis of 
dispensing records of patients in the United 
States who were prescribed a TNF antagonist 
(adalimumab 40 mg per 0.8-mL injection) 
from January 11, 2003, to August 13, 2009. 
Adalimumab is approved to treat rheumatoid 
arthritis, juvenile idiopathic arthritis, psoriatic 
arthritis, chronic plaque psoriasis, ankylosing 
spondylitis, and Crohn’s disease.22
The data were collected by Wolters Kluwer 
Pharma Solutions (Phoenix, AZ, USA) from 
pharmacy terminals in deidentified format 
in compliance with the Health Insurance 
Portability and Accountability Act of 1996. The 
patients and their dispensed prescriptions were 
longitudinally linked in the data. Wolters Kluwer 
Health provided a database as well as a codebook 
that interpreted the variables. The database had 
1,291,958 adalimumab prescription dispensing 
records, with each record corresponding to a 
prescription. Each record included variables 
such as the patient identification number; 
prescription drug name; United States national 
drug code;23 the dispensing date of the 
prescription; days of supply for the prescription; 
pharmacy type (specialty or retail pharmacy); 
reimbursement or payment type; the copayment 
or payment amount; and the patient’s birth 
year, sex, ethnicity, and annual income. 
Adalimumab prescriptions were identified 
through the United States national drug codes 
00074-3799-02, 00074-4339-02, 00074-4339-06, 
00074-4399-07, 00074-9374-02, 54569-5524-00, 
and 54868-4822-00. The data were reviewed 
and analyzed by a researcher at a university. 
The study was exempt from the review of the 
university institutional review board because the 
institutional review board determined that the 
data were deidentified.
Measures and Restructured Data
Various measures have been developed to 
estimate patients’ actual medication adherence, 
known as refill adherence, from administrative 
pharmacy data, depending on the availability 
of data variables.24 The measures include 
continuous single-interval measure of medication 
availability, continuous measure of medication 
acquisition, compliance rate, days-between-
fills adherence rate, continuous measure of 
medication gaps, continuous multiple-interval 
measure of oversupply, medication possession 
ratio, refill compliance rate, MRA, and proportion 
of days covered. After comparing these measures, 
Hess et al.24 recommended the use of MRA as 
the preferred measure because MRA provided 
the closest estimation of the direct observed 
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adherence. MRA equals total days of supply 
divided by the number of days evaluated, then 
multiplied by 100, which is a percentage and is 
capped at 100. Numerically, MRA ranges from 
0 to 100; 0 indicates that the patient did not 
comply at all with the refill instructions on the 
prescription and 100 indicates that the patient 
was 100% adherent to the refill instructions.
In this study, MRA was used to measure 
patients’ refill adherence, and patients who had 
only one prescription or only had prescriptions 
on one dispensation date were excluded, 
because the intention of the study was to 
examine the maintenance population. For each 
patient, the number of days evaluated was the 
number of days between the first and the last 
dispensation dates. Total days of supply were 
the sum of days of supply for each prescription, 
except the prescription on the last dispensation 
date. In addition, the total days of supply per 
prescription per patient, and the copayment or 
payment amount per prescription per patient 
were calculated.
The database was restructured using the 
following steps: (1) patients who had only one 
prescription or only had all prescriptions on one 
dispensation date were excluded; (2) patients 
who obtained the drug from more than one 
type of pharmacy, or who used more than one 
mechanism to reimburse or pay the prescription 
were excluded, because the aim was to identify 
a single value for patient’s pharmacy type, or 
their reimbursement/payment type; and (3) the 
database was organized such that each patient 
identification number (ie, each patient) was 
associated with a single case. Figure 1 displays 
the process of study sample selection.
In the restructured database, variables for each 
patient included the number of prescriptions; the 
number of days evaluated; total days of supply; 
total days of supply per prescription; MRA; 
pharmacy type (specialty or retail pharmacy); 
reimbursement or payment type (Blue Cross and 
Blue Shield plan members, members of federal 
insurance programs, or cash payers without 
insurance); the copayment or payment amount 
per prescription; and the patient’s age, sex, 
ethnicity, and annual income.
Data Analyses
Descriptive statistics or frequency analyses 
were performed for each variable, and the 
characteristics of patients between two types of 
pharmacy were compared. Student’s t-tests were 
used to compare the number of prescriptions, 
total days of supply, MRA, the copayment/
payment amount per prescription, and age 
between the two groups. Chi-square tests were 
Figure 1. Process of study sample selection.
Patients who used adalimumab 
(40 mg per 0.8-mL injection)
n=124,332
Patients who relled adalimumab 
n=103,801
Selection of patients who 
used specialty pharmacy
Patients who used only 
specialty pharmacy
n=66,425
Patients who used only 




is is the study sample 
for patients using 
specialty pharmacy
Patients who used only 




is is the study sample 
for patients using 
retail pharmacy
Patients who used only 
retail pharmacy
n=29,859
Selection of patients who 
used retail pharmacy
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used to compare reimbursement/payment type, 
sex, ethnicity, and annual income.
Bivariate correlations between variables 
were examined. A linear regression analysis 
using ordinary least squares was also 
conducted, in which the dependent variable 
was MRA and the independent variables 
included pharmacy type, reimbursement or 
payment type, copayment or payment amount 
per prescription, age, sex, ethnicity, and 
annual income. An independent categorical 
variable was coded as a dummy variable or a 
set of dummy variables and the group with the 
highest frequency of patients was set as the 
reference group. For the dependent variable, 
the percentage of MRA (which ranged from 0 
to 100) in the regression was used instead of 
its actual value (which ranged from 0 to 1). 
Collinearity was assessed by variance inflation 
factor, and it was not an issue.25 The Statistical 
Analysis System version 9.1 (SAS®, Cary, NC, 
USA) was used to restructure the original 
data and Statistical Package for Social Science 
version 16.0 (SPSS®, Chicago, IL, USA) was 
used to analyze the restructured data.
RESULTS
Of 124,322 patients, 86,079 met the selection 
criteria and were included in the analysis 
(Figure 1). Table 1 lists the characteristics of these 
patients. Seventy percent of patients obtained 
the medication from a specialty pharmacy. There 
was a wide range in terms of the patients’ ages 
(1–80 years) and copayment/payment amounts 
per prescription ($0–$27,840.21). The largest 
copayment/payment amount, $27,840.21, 
might be an outlier. Compared with patients 
using a retail pharmacy, those who used a 
specialty pharmacy had greater average values 
in total days of supply (379.39 vs. 236.03), days 
of supply per prescription (41.39 vs. 29.89), 
Table 1. Characteristics of patients identified.
Variables Values




 Total*, n 86,079




 Total*, n 86,079




 Total*, n 86,079
MRA
 Mean±SD, % 84.02±22.03
 Median, % 95.45
 Range, % 0.43-100
 Total*, n 86,079
Pharmacy type, n (%)
 Specialty pharmacy 60,126 (69.8)
 Retail pharmacy 25,953 (30.2)
 Total* 86,079 (100)
Reimbursement/payment type, n (%)
 Blue Cross and Blue Shield plans 79,062 (91.8)
 Federal programs† 4122 (4.8)
 Cash payers without insurance 2895 (3.4)
 Total* 86,079 (100)
Copayment/payment amount per prescription
 Mean±SD, $ 105.19±352.41
 Median, $ 29.63
 Range, $ 0-27,840.21
 Total*, n 85,536
Age
 Mean±SD, years 52.33±14.74
 Median, years 53
 Range, years 1-80
 Total*, n 83,055
Sex, n (%)
 Female 55,474 (67.1)
 Male 27,205 (32.9)
 Total* 82,680 (100)
Ethnicity, n (%)
 White 34,519 (81.2)
 Hispanic 2214 (5.2)
 Black 1696 (4.0)
 Asian 401 (0.9)
 Other 3699 (8.7)
 Total* 42,529 (100)
Annual income, n (%)
 <$30,000 4392 (10.3)
 $30,000-$49,999 11,369 (26.7)
 $50,000-$74,999 12,110 (28.5)
 >$74,999 14,658 (34.5)
 Total* 42,529 (100)
*Total numbers vary because of missing values.
†US federal programs included Medicare, veteran administration plan, 
and other federal programs.
MRA=medication refill adherence.
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Table 2. Comparison of patients using retail pharmacy vs. specialty pharmacy.
Variables* Patients using retail pharmacy Patients using specialty pharmacy
Number of prescriptions 
 Mean±SD 8.22±9.72 10.99±13.58
 Median 4 6
 Range 1-104 1-113
 Total†, n 25,953 60,126
Total days of supply
 Mean±SD 236.03±276.12 379.39±424.93
 Median 140 252
 Range 1-2340 1-3694
 Total†, n 25,953 60,126
Total days of supply per prescription 
 Mean±SD 29.89±12.55 41.39±22.19
 Median 28 28
 Range 1-322.5 1-168
 Total†, n 25,953 60,126
MRA
 Mean±SD, % 72.61±25.71 88.94±18.14
 Median, % 78.87 100
 Range, % 0.43-100 1.88-100
 Total†, n 25,953 60,126
Reimbursement/payment type, n (%)
 Blue Cross and Blue Shield plans 21,765 (83.9) 57,297 (95.3)
 Federal programs‡ 1860 (7.1) 2262 (3.8)
 Cash payers without insurance 2328 (9.0) 567 (0.9)
 Total† 25,953 (100) 60,126 (100)
Copayment/payment amount per prescription
 Mean±SD, $ 82.99±239.27 114.78±390.87
 Median, $ 21.67 30
 Range, $ 0-5448.99 0-27,840.21
 Total†, n 25,785 59,751
Age
 Mean±SD, years 54.40±14.75 51.41±14.65
 Median, years 55 53
 Range, years 4-80 1-80
 Total†, n 25,578 57,477
Sex, n (%)
 Female 17,868 (70.2) 37,607 (65.7)
 Male 7593 (29.8) 19,612 (34.3)
 Total† 25,461 (100) 57,219 (100)
Ethnicity, n (%)
 White 10,028 (81.0) 24,491 (81.2)
 Hispanic 641 (5.2) 1573 (5.2)
 Black 537 (4.3) 1159 (3.8)
 Asian 121 (1.0) 280 (0.9)
 Other 1059 (8.5) 2640 (8.8)
 Total† 12,386 (100) 30,143 (100)
Annual income, n (%)
 <$30,000 1495 (12.1) 2897 (9.6)
 $30,000-$49,999 3444 (27.8) 7925 (26.3)
 $50,000-$74,999 3333 (26.9) 8,777 (29.1)
 >$74,999 4114 (33.2) 10,544 (35.0)
 Total† 12,386 (100) 30,143 (100)
*Comparisons of all variables between two groups were significant at the 0.01 level. Student’s t-tests were used to compare number of prescriptions, total 
days of supply, total days of supply per prescription, MRA, copayment/payment amount per prescription, and age. Chi-square testes were used to compare 
the other variables.
†Total numbers vary because of missing values.
‡US federal programs included Medicare, veteran administration plan, and other federal programs.
MRA=medication refill adherence.
Adv Ther (2010) 27(8):523-532. 529
and MRA (88.94% vs. 72.61%; Student’s t-tests, 
P<0.01; Table 2).
Results of the regression analysis are presented 
in Table 3. Significant predictors (P<0.05) of 
MRA included pharmacy type, reimbursement/
payment type, copayment/payment amount per 
prescription, age, sex, and ethnicity. Pharmacy 
type was the strongest significant predictor 
for MRA. Copayment/payment amount per 
prescription and the patient’s age were also 
significant predictors, but the association was 
not strong. Compared with patients who used 
a specialty pharmacy, patients who used a retail 
pharmacy had a 16% lesser MRA, controlling 
for the other independent variables. When the 
other independent variables were controlled 
for, patients in federal insurance programs had 
a 1% greater MRA than did patients who were 
Blue Cross and Blue Shield plan members. Also, 
male patients had a 1% greater MRA than did 
female patients. Compared with white patients, 
Hispanic patients and black patients had a 2% 
lesser MRA.
DISCUSSION
To the authors’ knowledge, and based on a 
review of the literature, this study represents 
the first effort to examine the impact of two 
pharmacy types (specialty vs. retail pharmacy) 
as system factors on patients’ adherence to 
therapy with a TNF antagonist. As patients’ 
adherence can be affected by many factors12-14 
and administrative pharmacy data usually 
contain a small subset of these factors, the 
variables from administrative data may only 
explain a limited amount of variance in refill 
adherence. For instance, Schectman et al.26 
used pharmacy claims data to examine the 
impact of demographic and prescription 
characteristics on refill adherence, and the 
regression model explained 6.8% of the variance 
in refill adherence. In this study, the regression 
model explained 12% of variance in MRA. In 
particular, medication source contributed the 
most to explaining the variance of MRA and was 
the strongest predictor of MRA (standardized 
beta=–0.34,  P<0.01) ,  indicat ing that 
environmental factors (such as pharmacy type) 
play an important role in patients’ adherence.
The primary finding of the present study was 
that patients who used a specialty pharmacy 
had a refill adherence 16% greater than those 
who used a retail pharmacy. Although it was 
predicted that specialty pharmacies would be 
Table 3. Regression model of medication refill adherence.









 Retail pharmacy -16.38† -0.34†
Reimbursement/payment type§
 Federal programs 0.93◊ 0.01◊





Sex (male) ¶ 0.95† 0.02†
Ethnicity#
 Hispanic -1.63† -0.02†
 Black -2.09† -0.02†
 Asian 1.49 0.01
 Other -0.04 -0.00
Annual income☐
 <$30,000 -0.09 -0.00
 $30,000-$49,999 -0.24 -0.01
 $50,000-$74,999 0.16 0.00
*n=41,841 owing to missing values.
†Significant at the 0.01 level.
‡The reference group is specialty pharmacy.
§The reference group is Blue Cross and Blue Shield plans.
◊Significant at the 0.05 level.
¶The reference group is female.
#The reference group is white.
☐The reference group is >$74,999.
Df=degrees of freedom; MRA=medication refill adherence.
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more strongly associated with refill adherence 
than retail pharmacies, there could be reasons 
to support the opposite hypothesis as well. For 
example, a specialty pharmacy frequently uses 
mail order to deliver medications, whereas 
a retail pharmacy often has in-store sales of 
medications during patient visits. One might 
potentially predict that patients’ adherence 
at a retail pharmacy would be greater because 
a face-to-face encounter may better foster 
the patient-pharmacist relationship and 
improve patients’ adherence. Nonetheless, the 
study’s hypothesis was well supported by the 
regression results, which showed that specialty 
pharmacies more positively influenced 
patients’ refill adherence than did retail 
pharmacies. Thus, this study demonstrated 
the value of specialty pharmacies in terms of 
medication adherence.
In managed care, ensuring proper usage 
of specialty medications has presented a 
challenge to third-party payers. On one 
hand, owing to the high cost, nearly half of 
payers had restrictions on the distribution of 
specialty medications.27 On the other hand, 
owing to the complex care associated with 
specialty medications, payers have requested 
relevant pharmaceutical care services to assist 
patients with usage, especially from specialty 
pharmacies.8 Therefore, third-party payers 
have increasingly asked pharmaceutical 
manufacturers and specialty pharmacies for 
positive outcomes to justify providing these 
regimens and related services.8
Whereas pharmaceutical manufacturers are 
responsible for demonstrating the outcomes 
of specialty medications, specialty pharmacies 
need to demonstrate the outcomes associated 
with pharmaceutical care services, such as 
proactive refill management and medication 
adherence monitoring. In proactive refill 
management, reminder mailings, calls, or 
emails are sent to patients prior to the refill 
date; in medication adherence monitoring, 
pharmacists can contact the patients in a 
timely fashion if inadequate adherence is 
noticed. The data from the present study 
suggests that specialty pharmacies should be 
preferred over retail pharmacies for dispensing 
specialty medications. In addition, consistent 
with previous findings,13-15 it was found that 
reimbursement/payment type and patients’ 
sex and ethnicity affected medication 
adherence. This suggests that pharmaceutical 
care services, like proactive refill management, 
should be targeted more toward patients 
who are women, black, or Hispanic. It can 
be hypothesized that if specialty pharmacies 
increased the frequency of refill reminders to 
these groups, adherence might increase.
Usually, individual patients do not have 
choice of specialty pharmacy vs. retail 
pharmacy. The choice is generally made by 
insurance companies. Given that patients had 
a 16% greater MRA at a specialty pharmacy 
than a retail pharmacy, insurance companies 
should shift distribution of biologics from 
retail pharmacies to specialty pharmacies. 
Also, manufacturers should reevaluate the 
efficiency of delivering TNF antagonists 
and make appropriate adjustments to their 
strategies of managing marketing channels. 
The term marketing channel refers to how 
a product or service is sold or delivered 
from the producer to consumers28 and 
specialty and retail pharmacies represent two 
marketing channels used by pharmaceutical 
manufacturers  to distr ibute specialty 
medications. Manufacturers might reconsider 
the current approach and shift the emphasis 
to specialty pharmacies. Shifting to specialty 
pharmacies may also reduce the number of 
intermediaries between manufacturers and 
patients, improving inventory management.
Adv Ther (2010) 27(8):523-532. 531
Limitations
There were three limitations in this study. 
First, data were taken from dispensing records, 
and the information for each record or patient 
was limited. Data such as the patient’s medical 
condition, the severity of the condition, 
the use of other medications, forgetfulness, 
and the relationship between patients and 
healthcare providers were not available in the 
database. These factors may influence medical 
adherence. The bias from not evaluating these 
factors was considered nondifferential to the 
types of pharmacy and thus less likely to have 
an impact on the conclusion of the study. 
Second, refill adherence was used to estimate 
the actual adherence, which may not truly 
reflect the actual adherence. It was assumed 
that patients consumed the medication as 
prescribed after they obtained the medication 
on the day of dispensation.24 Some patients 
might not use the medication as prescribed after 
they obtained the medication. However, this 
misclassification of adherence was considered 
to be not related to pharmacy type, and, thus, 
it is less likely to have affected the conclusions 
of the study. Third, the majority of the samples 
were from Blue Cross and Blue Shield plans. 
The validation of the conclusion of the present 
study in other insured populations would 
increase the generalizability of the findings. 
Furthermore, future research can build on the 
results of this study by assessing the role of 
pharmacy type in patients’ adherence to other 
specialty medications. Whereas the present 
study involved retrospective design and 
secondary data analysis, other study designs 
(eg, prospective cohort design) and other 
techniques (eg, surveys or interviews) should 
be explored.
In conclusion, patients who used a specialty 
pharmacy to obtain a TNF antagonist had 
greater refill adherence than patients who 
used a retail pharmacy. Specialty pharmacies 
may be considered the preferred distribution 
channel for TNF antagonists.
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